Product Images Ivabradine
View Photos of Packaging, Labels & Appearance
- 51407-592-60OL .jpg - 51407 592 60OL
- 51407-593-60OL.jpg - 51407 593 60OL
- Image - 9afa6c68 f4c3 4d3b 92d7 765f19e0ba22 01
- Image - 9afa6c68 f4c3 4d3b 92d7 765f19e0ba22 02
- Image - 9afa6c68 f4c3 4d3b 92d7 765f19e0ba22 03
- Image - 9afa6c68 f4c3 4d3b 92d7 765f19e0ba22 04
- Image - 9afa6c68 f4c3 4d3b 92d7 765f19e0ba22 05
- Image - 9afa6c68 f4c3 4d3b 92d7 765f19e0ba22 92 2
Product Label Images
The following 8 images provide visual information about the product associated with Ivabradine NDC 51407-593 by Golden State Medical Supply, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
51407-592-60OL .jpg - 51407 592 60OL
This is a pharmaceutical product labeled with the NDC code 51407-592-60. It contains film-coated tablets with 5 mg of ivabradine hydrochloride. The pharmacist is advised to dispense the medication guide to each patient. The dosage information is available in the prescribing information. The package is child-resistant and should be stored at 25°C with excursions permitted between 15° - 30°C. The product is marketed by GSMS, Incorporated in Camarillo, CA, USA.*
51407-593-60OL.jpg - 51407 593 60OL

This text is a description of Ivabradine tablets for oral use. It includes important information such as dosage instructions, storage conditions, manufacturer details, and a reminder to keep the medication out of children's reach. The package is child-resistant and contains 60 film-coated tablets, each containing 7.5 mg of ivabradine. The medication guide is supposed to be dispensed to each patient. For more information, individuals can consult the prescribing information accompanying the tablets.*
Image - 9afa6c68 f4c3 4d3b 92d7 765f19e0ba22 03

This is a data table showing the proportion of subjects with heart failure hospitalization or cardiovascular death over time, indicated in months, based on the number of subjects at risk under the placebo and Coranor treatment. Placebo group has 3264 subjects at the start, with decreasing numbers over months. Coranor group starts with 3241 subjects. The data displayed can be utilized for analyzing and comparing the efficacy of the treatments in preventing heart failure hospitalizations and cardiovascular deaths.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.